Revisión por temas de las últimas publicaciones en las que han participado miembros del grupo

Archivado en Noticias

Opciones terapéuticas y EII

1. Mesenchymal stromal cells in the treatment of perianal fistulas in Crohn’s disease.
Castro-Poceiro J, Fernández-Clotet A, Panés J.
Immunotherapy. 2018 Oct;10(14):1203-1217.

2. Tofacitinib for the treatment of ulcerative colitis.
Fernández-Clotet A, Castro-Poceiro J, Panés J.
Expert Rev Clin Immunol. 2018 Nov;14(11):881-892

3. Does the Antitumor Necrosis Factor-α Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?
Maldonado-Pérez MB, Castro-Laria L, Caunedo-Álvarez A, Montoya-García MJ, Giner-García M, Argüelles-Arias F, Romero-Gómez M, Vázquez-Gámez MÁ.
J Clin Densitom. 2018 Aug 13.

Percepciones del paciente. Impacto y calidad de vida

1. Patients’ perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain.
Calvet X, Argüelles-Arias F, López-Sanromán A, Cea-Calvo L, Juliá B, de Santos CR, Carpio D.
Patient Prefer Adherence. 2018 Sep 18;12:1815-1823.

Predicción de respuesta y progresión

1. Endoscopic progression of ulcerative proctitis to proximal disease. Can we identify predictors of progression?
Huguet JM, Ferrer-Barceló L, Suárez P, Albert C, Gonzalez L, Castillo G, Boix C, García L, Gallego J, Sempere J.
Scand J Gastroenterol. 2018 Oct 23:1-5.

2. Persistent damage on magnetic resonance enterography in patients with Crohn’s disease in endoscopic remission.
Rimola J, Alfaro I, Fernández-Clotet A, Castro-Poceiro J, Vas D, Rodríguez S, Masamunt MC, Ordás I, Ricart E, Panés J.
Aliment Pharmacol Ther. 2018 Oct 22.

3. Fecal calprotectin is not superior to serum C-reactive protein or the Harvey-Bradshaw index in predicting postoperative endoscopic recurrence in Crohn’s disease.
Verdejo C, Hervías D, Roncero Ó, Arias Á, Bouhmidi A, Lorente R, Salueña I, Lucendo AJ.
Eur J Gastroenterol Hepatol. 2018 Oct 9.

4. Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study.

Burisch J, Katsanos KH, Christodoulou DK, Barros L, Magro F, Pedersen N, et al. ; Epi-IBD Group.
J Crohns Colitis. 2018 Oct 5.

5. Inflammatory bowel disease in patients over the age of 70 y. Does the disease duration influence its behavior?
Huguet JM, Iborra M, Bosca-Watts MM, Maroto N, Gil R, Cortes X, Hervás D, Paredes JM.
Scand J Gastroenterol. 2018 Sep 6:1-6.

6. Review article: the relationship between obesity, bariatric surgery, and inflammatory bowel disease.
Cañete F, Mañosa M, Clos A, Cabré E, Domènech E.
Aliment Pharmacol Ther. 2018 Oct;48(8):807-816.

Genética, inmunología, proteómica

1. ANP32E, a protein involved in steroid-refractoriness in ulcerative colitis, identified by a systems biology approach.
Lorén V, Garcia-Jaraquemada A, Naves JE, Carmona X, Mañosa M, Aransay AM, Lavin JL, Sánchez I, Cabré E, Manyé J, Domènech E.
J Crohns Colitis. 2018 Oct 17.

2. Clinical usefulness of proteomics in inflammatory bowel disease: A comprehensive review.
Gisbert JP, Chaparro M.
J Crohns Colitis. 2018 Oct 10.

3. Different Genetic Expression Profiles of Oxidative Stress and Apoptosis-Related Genes in Crohn’s Disease.
Iborra M, Moret I, Rausell F, Busó E, Cerrillo E, Sáez-González E, Nos P, Beltrán B.
Digestion. 2018 Oct 9:1-10.

archivado en Noticias | publicado el 5 de noviembre de 2018 | última actualización: 2 de noviembre de 2018 15:01
Formación EII
Canal de GETECCU en YouTube
Base de datos ENEIDA
Nuestros patrocinadores|lea nuestra política de patrocinio